These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34147352)

  • 21. Gene Expression-Related Changes in Morphologies of Organelles and Cellular Component Organization in Mucopolysaccharidoses.
    Gaffke L; Pierzynowska K; Rintz E; Cyske Z; Giecewicz I; Węgrzyn G
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Underestimated Aspect of Mucopolysaccharidosis Pathogenesis: Global Changes in Cellular Processes Revealed by Transcriptomic Studies.
    Gaffke L; Pierzynowska K; Podlacha M; Hoinkis D; Rintz E; Brokowska J; Cyske Z; Wegrzyn G
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32054071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Separation of sulfated urinary glycosaminoglycans by high-resolution electrophoresis for isotyping of mucopolysaccharidoses in Malaysia.
    Nor A; Zabedah MY; Norsiah MD; Ngu LH; Suhaila AR
    Malays J Pathol; 2010 Jun; 32(1):35-42. PubMed ID: 20614724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth impairment in mucopolysaccharidoses.
    Melbouci M; Mason RW; Suzuki Y; Fukao T; Orii T; Tomatsu S
    Mol Genet Metab; 2018 May; 124(1):1-10. PubMed ID: 29627275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathogenesis of Mucopolysaccharidoses, an Update.
    Fecarotta S; Tarallo A; Damiano C; Minopoli N; Parenti G
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Genetic aspects of mucopolysaccharidoses].
    Lacombe D; Germain DP
    Arch Pediatr; 2014 Jun; 21 Suppl 1():S22-6. PubMed ID: 25063380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses.
    Banecka-Majkutewicz Z; Jakóbkiewicz-Banecka J; Gabig-Cimińska M; Węgrzyn A; Węgrzyn G
    Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):461-8. PubMed ID: 22949095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanotechnology applied to treatment of mucopolysaccharidoses.
    Schuh RS; Baldo G; Teixeira HF
    Expert Opin Drug Deliv; 2016 Dec; 13(12):1709-1718. PubMed ID: 27322551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two-dimensional NMR spectroscopy of urinary glycosaminoglycans from patients with different mucopolysaccharidoses.
    Hochuli M; Wüthrich K; Steinmann B
    NMR Biomed; 2003 Jun; 16(4):224-36. PubMed ID: 14558120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic Base of Behavioral Disorders in Mucopolysaccharidoses: Transcriptomic Studies.
    Pierzynowska K; Gaffke L; Podlacha M; Węgrzyn G
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32050523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epilepsy in mucopolysaccharidosis disorders.
    Scarpa M; Lourenço CM; Amartino H
    Mol Genet Metab; 2017 Dec; 122S():55-61. PubMed ID: 29170080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mucopolysaccharidosis III: Molecular basis and treatment.
    Spahiu L; Behluli E; Peterlin B; Nefic H; Hadziselimovic R; Liehr T; Temaj G
    Pediatr Endocrinol Diabetes Metab; 2021; 27(3):201-208. PubMed ID: 34743503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessments of neurocognitive and behavioral function in the mucopolysaccharidoses.
    Shapiro EG; Escolar ML; Delaney KA; Mitchell JJ
    Mol Genet Metab; 2017 Dec; 122S():8-16. PubMed ID: 29128371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different?
    Węgrzyn G; Jakóbkiewicz-Banecka J; Narajczyk M; Wiśniewski A; Piotrowska E; Gabig-Cimińska M; Kloska A; Słomińska-Wojewódzka M; Korzon-Burakowska A; Węgrzyn A
    Med Hypotheses; 2010 Dec; 75(6):605-9. PubMed ID: 20732748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarker identification and trans-regulatory network analyses in esophageal adenocarcinoma and Barrett's esophagus.
    Lv J; Guo L; Wang JH; Yan YZ; Zhang J; Wang YY; Yu Y; Huang YF; Zhao HP
    World J Gastroenterol; 2019 Jan; 25(2):233-244. PubMed ID: 30670912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Mucopolysaccharidoses].
    Fukuda S; Sukegawa K; Tomatsu S; Orii T
    Nihon Rinsho; 1995 Dec; 53(12):3019-24. PubMed ID: 8577052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heparan sulfate proteoglycans: The sweet side of development turns sour in mucopolysaccharidoses.
    De Pasquale V; Pavone LM
    Biochim Biophys Acta Mol Basis Dis; 2019 Nov; 1865(11):165539. PubMed ID: 31465828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systems biology study of mucopolysaccharidosis using a human metabolic reconstruction network.
    Salazar DA; Rodríguez-López A; Herreño A; Barbosa H; Herrera J; Ardila A; Barreto GE; González J; Alméciga-Díaz CJ
    Mol Genet Metab; 2016 Feb; 117(2):129-39. PubMed ID: 26276570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutation in VPS33A affects metabolism of glycosaminoglycans: a new type of mucopolysaccharidosis with severe systemic symptoms.
    Kondo H; Maksimova N; Otomo T; Kato H; Imai A; Asano Y; Kobayashi K; Nojima S; Nakaya A; Hamada Y; Irahara K; Gurinova E; Sukhomyasova A; Nogovicina A; Savvina M; Yoshimori T; Ozono K; Sakai N
    Hum Mol Genet; 2017 Jan; 26(1):173-183. PubMed ID: 28013294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatic storage of glycosaminoglycans in feline and canine models of mucopolysaccharidoses I, VI, and VII.
    Haskins ME; Otis EJ; Hayden JE; Jezyk PF; Stramm L
    Vet Pathol; 1992 Mar; 29(2):112-9. PubMed ID: 1632054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.